Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

16 Oct 2025 07:00

RNS Number : 5665D
Sabre Insurance Group PLC
16 October 2025
 

 

16 October 2025

Sabre Insurance Group plc

Trading Update

Full-year profit guidance reiterated, Ambition 2030 initiatives on-track

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading motor insurance underwriters, today provides an update on trading for the period from 1 July 2025 to 30 September 2025.

Unaudited

Nine months ended

30 September

Year ended

31 December

 

2025

2024

% Change

 2024

Gross written premium - Motor Vehicle

£133.1m

£165.6m

(19.6)%

£209.9m

Gross written premium - Motorcycle

£8.7m

£8.2m

6.1%

£9.7m

Gross written premium - Taxi

£9.9m

£12.7m

(22.0)%

£16.8m

Gross written premium - Total

£151.7m

£186.5m

(18.7)%

£236.4m

Key Highlights

‒ Full-year profit guidance reiterated, expected to be in-line with 2024

‒ Pricing discipline maintained and policies continue to be written at target margins of 18% - 22%

‒ Cautious claims inflation assumptions fully covered, supporting an anticipated strong profit in 2025 and 2026 as well as continued target-level profitability into the medium-term

‒ Gross written premium continues at a healthy level despite broader market pricing remaining subdued

‒ £5 million share buyback programme completed

‒ Continued strong capital generation underpins confidence in the ability to make an attractive capital distribution at year-end

‒ Good progress towards Ambition 2030, and not impacted by the present cyclical market weakness

 

Market trends

‒ Continued signs of claims inflation moderating, now at a mid-single-digit level

‒ The fall in market pricing appears to be stabilising having seen prices fall consistently through the first half of the year

We continue to expect market pricing to increase in late 2025 or early 2026 to avoid significantly undermining 2026/2027 market-level profitability

 

Outlook

‒ In-line with previous guidance, full-year profit is expected to be in-line with 2024, as we execute on our pricing discipline and margin management strategy, with a net insurance margin within our target range

‒ We continue to expect a healthy if slightly reduced premium out-turn for the year as we maintain focus on maximising absolute profit by writing business at appropriate margins

‒ Beyond 2025, we foresee good profitability as we deliver on Ambition 2030

‒ Continued strong capital generation supports the Board's confidence in the ability to provide an attractive capital distribution at year-end

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"I continue to be pleased with our performance at the Q3 stage of 2025. Our long-term focus on margins over volume means we are confident of delivering a strong full-year result with profits in-line with 2024 with a very robust capital position, despite market-wide motor premium pricing weakness for large parts of 2025.

Because Sabre has focussed on maintaining pricing discipline through 2025, we are also confident of maintaining strong margins and delivering good profitability into 2026 and beyond.

Whilst it is slightly frustrating that the market has underpriced against on-going claims inflation, we had anticipated this, and it is factored into our business model. It is reassuring that we continue to write healthy levels of premium at our target margins during this part of the market cycle.

In recent weeks we have seen some positive momentum in our weekly premium levels and modest growth returning in our core motor book. At this stage this is driven by our own pricing initiatives rather than the anticipated market turn.

Our Ambition 2030 initiatives continue to develop at pace, and we remain confident on delivering on our targets. Combined with our long-term and stress-tested strategy, this means we can continue to deliver good performance at all points of the market cycle - growing and contracting as appropriate in the short-term, whilst delivering meaningful profit growth in the longer term."

 

 

Investor enquiries

01306 747 272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Teneo

sabre@teneo.com

James Macey White / Ffion Dash

 

LEI Code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFIFWIEISEIS
Date   Source Headline
13th Apr 20224:18 pmRNSNotice of AGM
12th Apr 20223:34 pmRNSDirector/PDMR Shareholding
8th Apr 20228:42 amRNSDirector/PDMR Shareholding
1st Apr 20227:13 amRNSDividend Declaration
1st Apr 20227:00 amRNSBoard Appointment
22nd Mar 20227:00 amRNSFinal Results
14th Mar 20221:22 pmRNSDirector Declaration
11th Mar 20221:50 pmRNSDirector/PDMR Shareholding
22nd Feb 20227:00 amRNSNotice of Results
21st Feb 202212:31 pmRNSHolding(s) in Company
11th Feb 202211:34 amRNSDirector/PDMR Shareholding
28th Jan 20227:00 amRNSNew Contract with Freeway Insurance Services Ltd
11th Jan 20222:27 pmRNSDirector/PDMR Shareholding
13th Dec 20211:37 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSAppointment of new additional broker
29th Nov 20217:00 amRNSDirectorate Change
11th Nov 20211:20 pmRNSDirector/PDMR Shareholding
10th Nov 20217:00 amRNSNew Contract as Exclusive Underwriter to MCE
5th Nov 202111:58 amRNSDirector/PDMR Shareholding
14th Oct 20212:27 pmRNSDirector/PDMR Shareholding
14th Oct 202111:41 amRNSDirector/PDMR Shareholding
14th Oct 20217:00 amRNSQ3 Trading Update
12th Oct 202112:06 pmRNSDirector/PDMR Shareholding
12th Oct 202112:02 pmRNSDirector Declaration
7th Oct 20217:00 amRNSNotice of Trading Update
17th Sep 20212:34 pmRNSDirector/PDMR Shareholding
17th Sep 20212:33 pmRNSDirector/PDMR Shareholding
13th Sep 202111:55 amRNSDirector/PDMR Shareholding
11th Aug 20219:51 amRNSDirector/PDMR Shareholding
30th Jul 202110:15 amRNSDirector/PDMR Shareholding
28th Jul 20213:14 pmRNSDirector/PDMR Shareholding
27th Jul 20217:00 amRNSHalf-year Report
13th Jul 202111:24 amRNSDirector/PDMR Shareholding
13th Jul 20217:00 amRNSNotice of Results
6th Jul 202111:00 amRNSHolding(s) in Company
2nd Jul 202112:50 pmRNSDirector/PDMR Shareholding
29th Jun 202111:39 amRNSHolding(s) in Company
22nd Jun 20213:46 pmRNSHolding(s) in Company
11th Jun 202110:53 amRNSDirector/PDMR Shareholding
21st May 20212:28 pmRNSDirector/PDMR Shareholding
21st May 20212:05 pmRNSDirector/PDMR Shareholding
21st May 202110:34 amRNSDirector/PDMR Shareholding
19th May 202112:49 pmRNSHolding(s) in Company
14th May 202111:46 amRNSResults of Annual General Meeting
14th May 20217:00 amRNSTrading Statement
11th May 20211:20 pmRNSDirector/PDMR Shareholding
22nd Apr 202110:00 amRNSDirector/PDMR Shareholding Replacement
22nd Apr 20219:51 amRNSDirector/PDMR Shareholding
14th Apr 20219:01 amRNSDirector/PDMR Shareholding
13th Apr 202111:12 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.